Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Flexion Therapeutics Inc. FLXN

Healthcare Drug Manufacturers - Major
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra... see more

Recent & Breaking News (NDAQ:FLXN)

Flexion Therapeutics Announces Changes to Board of Directors

GlobeNewswire March 6, 2015

Flexion Therapeutics Completes Enrollment in Pivotal Phase 2b Confirmatory Clinical Trial With Lead Compound FX006

GlobeNewswire February 24, 2015

Flexion Therapeutics to Present at RBC Capital Markets Healthcare Conference

GlobeNewswire February 17, 2015

Flexion Therapeutics Initiates Phase 3 Clinical Trial of FX006 in Patients With Osteoarthritis of the Knee

GlobeNewswire February 2, 2015

Flexion Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of Public Offering of Common Stock

GlobeNewswire December 17, 2014

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire December 12, 2014

Flexion Therapeutics Announces Public Offering of Common Stock

GlobeNewswire December 8, 2014

Flexion Therapeutics Announces That FDA Has Removed Clinical Hold on FX006

GlobeNewswire December 1, 2014

Flexion Therapeutics to Present at Stifel Healthcare Conference 2014

GlobeNewswire November 17, 2014

Flexion Therapeutics Reports Third-Quarter 2014 Financial Results

GlobeNewswire November 13, 2014

Flexion Therapeutics to Report Third-Quarter 2014 Financial Results

GlobeNewswire November 6, 2014

Flexion Therapeutics, Inc. (Nasdaq: FLXN) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire October 22, 2014

Flexion Therapeutics Announces Clinical Hold of FX006 Phase 2b Clinical Trial in Osteoarthritis of the Knee

GlobeNewswire September 17, 2014

Flexion Therapeutics Inc. (FLXN) Jumps 17.83% on September 10

Equities.com September 10, 2014

Flexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Candidate FX006

GlobeNewswire September 9, 2014

Flexion Therapeutics to Start FX006 Phase 3 Pivotal Trial in 2014; Following FDA Meeting, Development Plan Advanced by One Year

GlobeNewswire September 3, 2014

Flexion Therapeutics Reports Second-Quarter 2014 Financial Results

GlobeNewswire August 7, 2014

Flexion Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014

GlobeNewswire July 31, 2014

Flexion Therapeutics and Southwest Research Institute(R) (SwRI(R)) Sign Worldwide Exclusive License for Proprietary Microsphere Manufacturing Technologies

GlobeNewswire July 28, 2014

Flexion Therapeutics Announces Board Changes

GlobeNewswire July 24, 2014